[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Mesía R, Palmero R, Cos M, Vilajosana E, Vázquez S: Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report. Head Neck Oncol; 2010;2:3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report.
  • BACKGROUND: Symptom control is an important consideration in the choice of treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
  • Patients who demonstrate objective tumour responses to platinum-based chemotherapy are more likely to have symptom relief than those who do not have such responses.
  • A phase III trial (EXTREME) showed that adding the epidermal growth factor receptor (EGFR)-targeting IgG1 monoclonal antibody cetuximab to first-line platinum-based chemotherapy significantly prolongs progression-free and overall survival and increases response rate compared with platinum-based chemotherapy alone.
  • We report here the case of a 60-year old female with recurrent squamous cell carcinoma of the gum who had rapid palliation of symptoms and reduction of facial disease mass following treatment with a combination of carboplatin/5-fluorouracil (5-FU) and cetuximab.
  • CASE PRESENTATION: The patient was diagnosed with T4N0 M0 disease of the oral cavity in November 2006 and underwent surgery, with R0 resection, followed by adjuvant radiotherapy and concomitant cisplatin chemotherapy.
  • The patient received 4 21-day cycles of carboplatin (AUC 5), 5-FU (1,000 mg/m2/day for 4 days) and cetuximab (400 mg/m2 initial dose followed by subsequently weekly doses of 250 mg/m2), with continuation of cetuximab monotherapy at the end of this time, and pain relief with topical fentanyl and oral morphine.
  • After 7 days of treatment, pain had reduced to 2/10, with discontinuation of morphine after 4 days, and the facial mass had reduced to 70 mm.
  • After 2 cycles of treatment, the facial mass had decreased to 40 mm.
  • After 3 cycles of treatment, pain and facial oedema had resolved completely and a cervical computed tomography scan showed a marked reduction in tumour mass.
  • CONCLUSION: This case illustrates the rapid reduction of tumour mass and disease-associated pain and oedema that can be achieved with a combination of platinum-based chemotherapy and cetuximab in recurrent and/or metastatic SCCHN.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2653-8 [16763279.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3562-7 [15908667.001]
  • [Cites] Ann Oncol. 1997 May;8(5):445-9 [9233523.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(7):1135-41 [8758243.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1245-51 [1634913.001]
  • [Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):21-8 [19897418.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • (PMID = 20181021.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; BG3F62OND5 / Carboplatin; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2832769
  • [General-notes] NLM/ Original DateCompleted: 20100629
  •  go-up   go-down


2. Ogiuchi Y, Maruoka Y, Ando T, Kobayashi M, Ogiuchi H: Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma. Acta Histochem Cytochem; 2008 Jun 27;41(3):39-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma.
  • We conducted a clinicopathologic study on protein and mRNA levels of thymidylate synthase (TS), thymidine phosphorylase (TP) and orotate phosphoribosyl transferase (OPRT) using biopsy tissue specimens before treatment.
  • We studied the mRNA and protein expression as effect predictive factors in chemotherapy.
  • The subjects consisted of 20 cases of untreated oral squamous cell carcinoma who had undergone chemotherapy with TS-1 (16 males and 4 females, tongue in 8 cases, upper gingiva in 3 cases, lower gingiva in 3 cases, buccal mucosa in 5 cases and floor of the mouth in 1 case).
  • Furthermore, regarding males who were less than 70 years of age, stage I and II, well differentiated type and tongue, TS mRNA expression of the responders were lower than that for the nonresponders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1486-92 [14562021.001]
  • [Cites] Oncol Rep. 2006 Jun;15(6):1417-23 [16685374.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Dec;94(6):717-23 [12464897.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):42-9 [10618604.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2371-6 [9796967.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3223-9 [9336359.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Acta Otolaryngol. 2006 Dec;126(12):1295-302 [17101591.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Mar;35(3):265-9 [16257511.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):884-9 [16189518.001]
  • [Cites] Oral Oncol. 2005 Mar;41(3):276-82 [15743690.001]
  • [Cites] J Am Coll Surg. 2005 Mar;200(3):336-44 [15737843.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1245-50 [15354215.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4116-24 [14519634.001]
  • [Cites] Oral Oncol. 2006 Oct;42(9):880-7 [16757204.001]
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):967-73 [15316940.001]
  • (PMID = 18636111.001).
  • [ISSN] 0044-5991
  • [Journal-full-title] Acta histochemica et cytochemica
  • [ISO-abbreviation] Acta Histochem Cytochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2447914
  • [Keywords] NOTNLM ; oral cancer / orotate phosphoribosyl transferase / thymidine phosphorylase / thymidylate synthase
  •  go-up   go-down


3. Momoi K, Sugita Y, Ishihara M, Satoh K, Kikuchi H, Hashimoto K, Yokoe I, Nishikawa H, Fujisawa S, Sakagami H: Cytotoxic activity of styrylchromones against human tumor cell lines. In Vivo; 2005 Jan-Feb;19(1):157-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic activity of styrylchromones against human tumor cell lines.
  • A total of 6 newly-synthesized styrylchromones (SC-1 approximately SC-6) were compared for their cytotoxic activity against three normal oral human cells (gingival fibroblast HGF, pulp cell HPC, periodontal ligament fibroblast HPLF) and four human tumor cell lines (squamous cell carcinoma HSC-2, HSC-3, submandibular gland carcinoma HSG, promyelocytic leukemia HL-60).
  • All compounds showed higher cytotoxic activity against tumor cell lines than against normal cells.
  • The highly tumor-specific cytotoxic action and apoptosis-inducing capability of SC-3 and SC-5 suggest their applicability for cancer chemotherapy.
  • [MeSH-major] Antineoplastic Agents / toxicity. Carcinoma, Squamous Cell / drug therapy. Chromones / chemistry. Chromones / toxicity. Mouth Neoplasms / drug therapy. Submandibular Gland Neoplasms / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Caspases / metabolism. Cell Line. Cell Line, Tumor. Dental Pulp / cytology. Dental Pulp / drug effects. Dental Pulp / metabolism. Drug Screening Assays, Antitumor. Electron Spin Resonance Spectroscopy. Electrophoresis, Agar Gel. Enzyme Activation / drug effects. Fibroblasts / drug effects. Fibroblasts / metabolism. Gingiva / cytology. HL-60 Cells. Humans. Periodontal Ligament / cytology. Structure-Activity Relationship

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15796168.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chromones; EC 3.4.22.- / Caspases
  •  go-up   go-down


Advertisement
4. Sakagami H, Asano K, Satoh K, Takahashi K, Terakubo S, Shoji Y, Nakashima H, Nakamura W: Anti-stress activity of mulberry juice in mice. In Vivo; 2006 Jul-Aug;20(4):499-504
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Morus / chemistry. Phytotherapy. Plant Extracts / pharmacology. Stress, Psychological / drug therapy
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / drug therapy. Cell Line, Tumor. Cell Survival / drug effects. Cells, Cultured. Dental Pulp / cytology. Dose-Response Relationship, Drug. Fibroblasts / drug effects. Fibroblasts / metabolism. Free Radical Scavengers / metabolism. Gingiva / cytology. Humans. Immersion / adverse effects. Leukemia / pathology. Lipid Peroxidation / drug effects. Mice. Mice, Inbred BALB C. Mouth Neoplasms / drug therapy. Periodontal Ligament / cytology. T-Lymphocytes / drug effects. T-Lymphocytes / metabolism. Time Factors

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Stress.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16900780.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Free Radical Scavengers; 0 / Plant Extracts
  •  go-up   go-down


5. Misra S, Chaturvedi A, Misra NC: Management of gingivobuccal complex cancer. Ann R Coll Surg Engl; 2008 Oct;90(7):546-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Squamous cell carcinoma of the oral cavity ranks as the 12th most common cancer in the world and the 8th most frequent in males.
  • The search terms carcinoma oral cavity, and cancer oral cavity, buccal mucosa, gingiva, gingivobuccal complex, and alveolus cancer/carcinoma were used.
  • RESULTS: Treatment of gingivobuccal complex cancer is primarily surgical.
  • Radical neck dissection, or its modification, is the standard treatment for the node-positive neck.
  • Supraomohyoid neck dissection is the accepted treatment for the node-negative neck.
  • Radiotherapy is usually not the preferred modality of treatment for early gingivobuccal complex cancer.
  • It is used either as postoperative adjuvant treatment or as definitive treatment for advanced cancer with or without chemotherapy.
  • Chemotherapy has been used as neo-adjuvant, adjuvant or palliative treatment.
  • Advanced cancers constitute a major proportion of patients presenting for treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Gingival Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Neck Dissection / methods. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] JAMA. 2007 Jul 4;298(1):70-82 [17609492.001]
  • [Cites] Br J Oral Maxillofac Surg. 2001 Dec;39(6):411-8 [11735134.001]
  • [Cites] Head Neck. 2002 Mar;24(3):282-9 [11891961.001]
  • [Cites] Lancet Oncol. 2000 Sep;1(1):37-42 [11905687.001]
  • [Cites] Head Neck. 1995 May-Jun;17(3):199-203 [7782204.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1995;252(3):143-5 [7662347.001]
  • [Cites] Head Neck. 1995 Mar-Apr;17(2):119-23 [7558808.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Jun;122(6):634-8 [8639295.001]
  • [Cites] Eur J Surg Oncol. 1996 Oct;22(5):502-4 [8903493.001]
  • [Cites] Am J Surg. 1996 Dec;172(6):650-3 [8988669.001]
  • [Cites] Am J Surg. 1996 Dec;172(6):654-7 [8988670.001]
  • [Cites] Am J Surg. 1998 Nov;176(5):422-7 [9874426.001]
  • [Cites] Head Neck. 1999 Jan;21(1):39-42 [9890349.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):827-41 [10074914.001]
  • [Cites] Head Neck. 1999 Mar;21(2):104-10 [10091977.001]
  • [Cites] Br J Oral Maxillofac Surg. 1999 Jun;37(3):205-9 [10454028.001]
  • [Cites] Am J Surg. 1999 Jul;178(1):73-7 [10456709.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):778-85 [15599855.001]
  • [Cites] Lancet Oncol. 2001 May;2(5):261-9 [11905780.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 May;128(5):600-3 [12003599.001]
  • [Cites] Head Neck. 2002 Oct;24(10):921-4 [12369070.001]
  • [Cites] Oncology. 2002;63(4):338-45 [12417788.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):327-33 [12525526.001]
  • [Cites] World J Surg. 2003 Jul;27(7):805-10 [14509511.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Nov;61(11):1289-96 [14613085.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 Dec;129(6):713-9 [14663440.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1743-52 [15117998.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 4):3-10 [15124127.001]
  • [Cites] Semin Oncol. 2004 Jun;31(3):382-93 [15190496.001]
  • [Cites] Eur J Surg Oncol. 2004 Sep;30(7):804-6 [15296998.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):365-73 [15380568.001]
  • [Cites] Head Neck. 2004 Oct;26(10):897-902 [15390193.001]
  • [Cites] Head Neck Surg. 1987 Jan-Feb;9(3):157-61 [3623945.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1326-31 [3345488.001]
  • [Cites] Indian J Cancer. 1987 Sep;24(3):167-71 [3450582.001]
  • [Cites] Head Neck. 1989 Mar-Apr;11(2):111-22 [2722487.001]
  • [Cites] Head Neck. 1990 Nov-Dec;12(6):476-82 [2258286.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan;25(1):17-21 [8416876.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1993;250(1):11-7 [8466744.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Sep;119(9):958-63 [8357596.001]
  • [Cites] Indian J Cancer. 1993 Dec;30(4):176-80 [8206500.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):391-4 [7977957.001]
  • [Cites] Br J Oral Maxillofac Surg. 1994 Dec;32(6):347-59 [7848993.001]
  • [Cites] Indian J Cancer. 1994 Dec;31(4):235-9 [7875724.001]
  • [Cites] Br J Oral Maxillofac Surg. 1995 Feb;33(1):3-8 [7718525.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):413-6 [10722019.001]
  • [Cites] Otolaryngol Clin North Am. 2005 Feb;38(1):37-46, viii [15649497.001]
  • [Cites] Head Neck. 2005 Jul;27(7):597-602 [15825204.001]
  • [Cites] Head Neck. 2005 Sep;27(9):739-47 [16047368.001]
  • [Cites] Oral Oncol. 2006 Jan;42(1):14-25 [15979381.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Mar;6(3):405-17 [16503857.001]
  • [Cites] Head Neck. 2001 Oct;23(10):907-15 [11592239.001]
  • (PMID = 18701010.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 57
  • [Other-IDs] NLM/ PMC2728300
  •  go-up   go-down


6. Nishikawa M, Tsuzaki Y, Maoka K, Nishida T, Sakamoto K, Yamamoto G: [A case report--a patient with gingiva carcinoma showing complete remission after combination chemotherapy with nedaplatin and 5-fluorouracil]. Gan To Kagaku Ryoho; 2004 Sep;31(9):1383-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report--a patient with gingiva carcinoma showing complete remission after combination chemotherapy with nedaplatin and 5-fluorouracil].
  • We report a patient showing a complete remission after combination chemotherapy with nedaplatin and 5-fluorouracil (5-FU).
  • A 63-year-old man was admitted to our hospital for advanced carcinoma of gingiva.
  • This combination chemotherapy resulted in a complete remission of the tumor after 2 weeks.
  • There has been no sign of recurrence for 6 months after the chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Gingival Neoplasms / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Male. Mandible. Middle Aged. Organoplatinum Compounds / administration & dosage. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15446561.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Tsurumaru D, Kuroiwa T, Yabuuchi H, Hirata H, Higaki Y, Tomita K: Efficacy of intra-arterial infusion chemotherapy for head and neck cancers using coaxial catheter technique: initial experience. Cardiovasc Intervent Radiol; 2007 Mar-Apr;30(2):207-11
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of intra-arterial infusion chemotherapy for head and neck cancers using coaxial catheter technique: initial experience.
  • The aim of this study was to evaluate the efficacy of intra-arterial infusion chemotherapy for head and neck cancers using a coaxial catheter technique: the superficial temporal artery (STA)-coaxial catheter method.
  • Thirty-one patients (21 males and 10 females; 37-83 years of age) with squamous cell carcinoma of the head and neck (maxilla, 2; epipharynx, 4; mesopharynx, 8; oral floor, 4; tongue, 10; lower gingiva, 1; buccal mucosa, 2) were treated by intra-arterial infusion chemotherapy.
  • Four patients were excluded from the tumor-response evaluation because of a previous operation or impossibility of treatment due to catheter trouble.
  • External radiotherapy was administered during intra-arterial chemotherapy at a total dose of 21-70.5 Gy.
  • Injury and dislocation of the microcatheter occurred 10 times in 7 patients.
  • Catheter infection was observed three times in each of two patients, and catheter occlusion and vasculitis occurred in two patients.
  • Intra-arterial infusion chemotherapy via the STA-coaxial catheter method could have potential as a favorable treatment for head and neck tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Catheterization, Peripheral / methods. Head and Neck Neoplasms / drug therapy. Infusions, Intra-Arterial
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Brachytherapy. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Temporal Arteries. Treatment Outcome. Tumor Burden / drug effects. Tumor Burden / radiation effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17216381.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


8. Yamamoto K, Obara S, Mishima K, Nakamura H, Yoshimura Y: [An advanced case of squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to chemotherapy with TS-1]. Gan To Kagaku Ryoho; 2004 Apr;31(4):635-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An advanced case of squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to chemotherapy with TS-1].
  • We report a case of advanced squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to oral chemotherapy with TS-1.
  • We carried out chemotherapy with TS-1 50 mg/day, without surgical treatment.
  • Adverse drug reactions, including vomiting, leukopenia and thrombopenia, forced a stop of the administration of TS-1.
  • Although she finally died of in senescence 2 months from the cease of administration, there was no recurrence of the cancer at the time.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Gingival Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Mouth Neoplasms / drug therapy. Mouth Neoplasms / pathology. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Administration Schedule. Drug Combinations. Female. Humans. Leukopenia / chemically induced. Mouth Mucosa / pathology. Neoplasm Invasiveness. Remission Induction. Thrombocytopenia / chemically induced. Vomiting, Anticipatory / etiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15114716.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


9. Yamamoto G, Shimada T, Nishida T, Ishida Y, Iba T, Nakata T, Ohtsuki T, Takigami K, Yamaguchi Y, Yoshitake K, Tanaka A, Tsuda Y: [Evaluation of a combination chemotherapy with nedaplatin and 5-FU for oral cancers]. Gan To Kagaku Ryoho; 2001 Aug;28(8):1111-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of a combination chemotherapy with nedaplatin and 5-FU for oral cancers].
  • Nedaplatin (cis-diammine-glycolato platinum: CDGP) is a platinum compound with a molecular weight of 303.18 that was recently developed in Japan.
  • In this study, we performed combined therapy of CDGP and fluorouracil (5-FU) for 8 patients with oral cancers, and evaluated the results to elucidate the clinical effect and adverse side effects.
  • The subjects were 8 patients with squamous cell carcinoma (5 males and 3 females aged 33-65 years).
  • The primary carcinoma regions were the tongue in 5 patients, oral floor in 2 patients, and mandibular gingiva in 1 patient.
  • Although the oral cancers in this study were extroverted superficial ulcerative cancers, and the number of patients was low at 8, this combined therapy is considered useful and worth evaluating in further accumulated cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Remission Induction

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11525027.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Lo WL, Kao SY, Chi LY, Wong YK, Chang RC: Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg; 2003 Jul;61(7):751-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival.
  • PURPOSE: The study goal was to determine which clinical features correlated with 5-year survival in patients surgically treated for oral squamous cell carcinoma (OSCC) in Taiwan.
  • PATIENTS AND METHODS: The records of 378 OSCC patients surgically treated with or without chemotherapy and radiotherapy were reviewed retrospectively.
  • Tumors occurred mainly at the buccal mucosa (BM) (100 of 378, 26.5%), gingiva (105 of 378, 27.8%), and tongue (103 of 378, 27.2%).
  • Neck nodal metastasis occurred frequently at the floor of the mouth (in >60% of cases), followed by the gingiva (45.7%), buccal mucosa (34%), and tongue (20.4%), whereas early distant metastasis was rare (5.3%).
  • OSCC at the BM and gingiva was most (and at the tongue least) associated with risk factors of BQ use and smoking.
  • CONCLUSIONS: Our data suggest that early treatment is the key to increasing the survival of OSCC patients.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Mouth Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Alcohol Drinking / adverse effects. Areca / adverse effects. Chemotherapy, Adjuvant. Female. Humans. Linear Models. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Sex Factors. Smoking / adverse effects. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12856245.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Inagi K, Takahashi H, Okamoto M, Nakayama M, Makoshi T, Nagai H: Treatment effects in patients with squamous cell carcinoma of the oral cavity. Acta Otolaryngol Suppl; 2002;(547):25-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment effects in patients with squamous cell carcinoma of the oral cavity.
  • A total of 221 patients (155 males, 66 females; stage I, n = 55: stage II, n = 58; stage III, n = 57; stage IV, n = 51) with squamous cell carcinoma of the oral cavity were studied.
  • Tumor localization was as follows: cancer of the tongue, n = 161; cancer of the oral floor, n = 28; cancer of the hard palate, n = 12; cancer of the buccal mucosa, n = 11; and cancer of the gingiva, n = 9.
  • In order to compare the effect of different treatments, three major treatment groups were defined, namely a surgery group, a radiotherapy group and a combination treatment group.
  • No significant difference in regional control rates was observed between the treatment groups.
  • [MeSH-major] Antineoplastic Protocols. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Mouth / drug effects. Mouth / radiation effects. Mouth Neoplasms / mortality. Mouth Neoplasms / therapy. Outcome Assessment (Health Care)
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Severity of Illness Index. Survival Rate


12. Tsuchiya Y, Noguchi T, Matsumoto K, Matsumura T, Hoshi K, Ito H, Osano H, Jinbu Y, Kusama M: [Clinical effects of concurrent chemoradiotherapy (hyperfractionation and cisplatin/5-fluorouracil) for patients with advanced oral squamous cell carcinoma]. Gan To Kagaku Ryoho; 2009 Jan;36(1):101-3
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical effects of concurrent chemoradiotherapy (hyperfractionation and cisplatin/5-fluorouracil) for patients with advanced oral squamous cell carcinoma].
  • Six patients with advanced oral squamous cell carcinoma were treated with preoperative concurrent chemoradiotherapy.
  • Chemotherapy consisting of CDDP(60 to 70 mg/m(2), day 1)and 5-FU(600 to 700 mg/m(2), day 1 to 5)with concurrent radiotherapy was accelerated hyperfractionation to target volume of 43-63 Gy.
  • The clinical effect of this therapy on the primary tumor and cervical lymph node was examined in patients who visited our university hospital from 1994 to 2004.
  • The primary sites were the tongue in 3, lower gingiva in 2, and upper gingiva in 1 patient(s).
  • In terms of adverse effects, all cases developed nausea, mucositis and leucopenia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Fluorouracil / therapeutic use. Mouth Neoplasms / drug therapy. Mouth Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Combined Modality Therapy / adverse effects. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Serpins / blood

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19151572.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Serpins; 0 / squamous cell carcinoma-related antigen; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Nakatani K, Nakamura M, Uzawa K, Wada T, Seki N, Tanzawa H, Fujita S: Establishment and gene analysis of a cisplatin-resistant cell line, Sa-3R, derived from oral squamous cell carcinoma. Oncol Rep; 2005 Apr;13(4):709-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and gene analysis of a cisplatin-resistant cell line, Sa-3R, derived from oral squamous cell carcinoma.
  • Cisplatin (CDDP) is widely used for chemotherapy of many malignancies, especially of oral squamous cell carcinoma (SCC).
  • However, because the mechanism of resistance to CDDP is unclear, we established a CDDP-resistant cell line, Sa-3R, from a CDDP-sensitive cell line, Sa-3, which was derived from moderately differentiated SCC of the lower gingiva.
  • Comparing gene expression levels in the cell lines using an in-house cDNA microarray, which represented 2,201 oral disease origin genes, many differentially expressed genes were identified.
  • The Sa-3/Sa-3R cell lines could be useful to identify the candidates responsible for the mechanism of CDDP-resistance and the up- or down-regulated genes identified by the gene expression profiles in the Sa-3R cell line may be, in part, associated with the mechanism.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Cell Line, Tumor. Cisplatin / pharmacology. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Mouth Neoplasms / genetics. Mouth Neoplasms / pathology
  • [MeSH-minor] Biopsy. Cell Proliferation. Coloring Agents / pharmacology. DNA, Complementary / metabolism. Down-Regulation. Humans. Inhibitory Concentration 50. Male. Oligonucleotide Array Sequence Analysis. Phenotype. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Time Factors. Up-Regulation


14. Togashi K, Hirahara H, Sugawara M, Oguma F, Miyamura H, Sato Y: [Pneumothorax due to pulmonary metastasis of gingival carcinoma: report of a case]. Kyobu Geka; 2003 Jan;56(1):55-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pneumothorax due to pulmonary metastasis of gingival carcinoma: report of a case].
  • A 72-year-old woman developed left pneumothorax 14 months after the first operation of a gingival carcinoma.
  • They seemed to be pulmonary metastasis from a carcinoma of gingiva and one of them ruptured into the pleural cavity.
  • Postoperative histological examination revealed that both of the lesions were moderately differentiated squamous cell carcinoma and they were the same histological findings as the gingival carcinoma excised previously.
  • Pulmonary metastasis from a carcinoma of gingiva is rare, while it may be thought 1% of metastatic lung tumors.
  • And also pulmonary metastasis is unusual cause of pneumothorax, especially without chemotherapy for it.
  • We reported the very rare case of pneumothorax due to pulmonary metastasis from a carcinoma of gingiva.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / secondary. Gingival Neoplasms / pathology. Lung Neoplasms / complications. Lung Neoplasms / secondary. Pneumothorax / etiology

  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12607255.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Okutomi T, Kato Y, Ichihara H, Hyodo I, Fujitsuka H, Yasuda S, Tatematsu N: [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment]. Gan To Kagaku Ryoho; 2000 Jan;27(1):65-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment].
  • A combination of radiotherapy and chemotherapy is a usual treatment method for malignant head and neck tumors, however chemoradiotherapy is associated with hematopoietic impairment and serious stomatitis in patients.
  • The clinical effects and evaluation of hematopoietic activity (e.g., leukocyte count) and the degree of stomatitis under adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer were investigated for preoperative cancer therapy.
  • The 18 patients, who had oral squamous cell carcinomas (5 of the tongue, 4 of the mandibular gingiva, 3 of the maxillary gingiva, 1 of the floor of the mouth, 3 of the buccal mucosa, and 2 others), were treated with this combination of adjuvant therapy with Ancer 20 injection, from March, 1991 to March, 1997.
  • They were injected with Ancer 20 (twice a week, 40 micrograms) during the cancer treatment period.
  • We investigated hematopoietic activity, (e.g., leukocyte and platelet counts) and the degree of stomatitis periodically, before and after the combined radiotherapy and chemotherapy treatment period.
  • These results suggest that Ancer 20 injection may generally improve various dysfunctions due to hematopoietic impairment by radiotherapy combined with chemotherapy, and improve immunological factors.
  • We conclude that Ancer 20 injection is a useful adjuvant treatment for oral cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Leukopenia / prevention & control. Mouth Neoplasms / drug therapy. Radiation-Protective Agents / administration & dosage. Stomatitis / prevention & control
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Leukocyte Count. Lipids / administration & dosage. Mannans / administration & dosage. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10660735.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Lipids; 0 / Mannans; 0 / Radiation-Protective Agents; 0 / specific substance maruyama
  •  go-up   go-down


16. Harada K, Sato M, Ueyama Y, Nagayama M, Hamakawa H, Nagahata S, Yoshimura Y, Osaki T, Ryoke K, Oral Cancer Study Group of Chugoku-Shikoku: Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma. Anticancer Drugs; 2008 Jan;19(1):85-90
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma.
  • The aim of this study was to investigate the efficacy and safety of an oral fluoropyrimidine anticancer agent, S-1, in patients with oral squamous cell carcinoma.
  • Patients with pathologically confirmed squamous cell carcinoma and at least one measurable lesion were enrolled.
  • The sites of the primary tumor were the gingiva (n=18), the tongue (n=12), the palate (n=5), the oral floor (n=4), the buccal mucosa (n=1), and the labial mucosa (n=1).
  • A median of two cycles of treatment (range, 1-5) was administered.
  • S-1 exhibits definite antitumor activity in patients with oral squamous cell carcinoma and is well tolerated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Drug Combinations. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043133.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


17. Iwabuchi H, Takamori K, Honma H, Asanami S, Tanaka Y: [A case of mandibular gingival cancer T4N0M0 which markedly responded to a combined therapy of nedaplatin with 5-fluorouracil]. Gan To Kagaku Ryoho; 2001 Sep;28(9):1273-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of mandibular gingival cancer T4N0M0 which markedly responded to a combined therapy of nedaplatin with 5-fluorouracil].
  • We recently experienced a case of mandibular gingival cancer T4N0M0 which markedly responded to a combination therapy of nedaplatin (254-S) with 5-fluorouracil (5-FU).
  • The patient was a 68-year-old male who visited our department with the main complaint of ulceration in the left mandibular gingiva.
  • Biopsy revealed a moderately differentiated squamous cell carcinoma which extended to the mandible, mandibular gingiva, buccal mucosa, half tongue and oral floor on the left side of the face.
  • As a neoadjuvant chemotherapy (NAC), 254-S at a dose of 100 mg/m2 was intravenously administered on day 1, while 5-FU at a dose of 700 mg/m2/day was intravenously administered from day 1 to 5 in succession.
  • Pathological examination of the extracted tissues showed tumor cells in the tongue only, indicating an excellent effect of this combination therapy of 254-S and 5-FU.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Gingival Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Male. Mandible. Organoplatinum Compounds / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11579639.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Koharazawa H, Yamaji S, Takasaki H, Takabayashi M, Fujimaki K, Taguchi J, Kanamori H, Ishigatsubo Y: [Triple secondary malignancy of gingiva, palate and esophagus after an allogeneic bone marrow transplantation for cutaneous T-cell lymphoma]. Rinsho Ketsueki; 2005 Jul;46(7):496-500
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Triple secondary malignancy of gingiva, palate and esophagus after an allogeneic bone marrow transplantation for cutaneous T-cell lymphoma].
  • A 31-year-old man was diagnosed as having cutaneous T-cell lymphoma in January 1994.
  • He received an allogeneic bone marrow transplantation (BMT) from an HLA-matched sibling donor in May 1995, because of refractoriness to chemotherapy.
  • The patient had been treated with immunosuppressants including prednisolone and cyclosporin A for chronic graft-versus-host disease (GVHD) of the extensive type following acute GVHD.
  • Five years after the BMT, he developed moderately differentiated squamous cell carcinoma (SCC) on the mandibular gingival mucosa and underwent surgical resection.
  • Furthermore, 6 years after the BMT well differentiated SCC developed on his palate and was resected.
  • Concurrently, he was diagnosed as having esophageal cancer (poorly differentiated SCC) and underwent a subtotal esophagotomy.
  • One year later he had a recurrence of the esophageal cancer with dysphagia and was treated with radiation and chemotherapy.
  • [MeSH-major] Bone Marrow Transplantation. Carcinoma, Squamous Cell. Esophageal Neoplasms. Gingival Neoplasms. Lymphoma, T-Cell, Cutaneous / therapy. Neoplasms, Second Primary. Palatal Neoplasms. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Graft vs Host Disease / complications. Humans. Immunosuppressive Agents / adverse effects. Male. Transplantation, Homologous. Treatment Outcome. Whole-Body Irradiation / adverse effects


19. Tei K, Totsuka Y, Iizuka T, Ohmori K: Marginal resection for carcinoma of the mandibular alveolus and gingiva where radiologically detected bone defects do not extend beyond the mandibular canal. J Oral Maxillofac Surg; 2004 Jul;62(7):834-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marginal resection for carcinoma of the mandibular alveolus and gingiva where radiologically detected bone defects do not extend beyond the mandibular canal.
  • PURPOSE: The study goal was to investigate the adequacy of marginal resection of the mandibular bone in cases of squamous cell carcinomas of the lower alveolus and gingiva where the radiologically detected bone defect does not extend beyond the mandibular canal.
  • PATIENTS AND METHODS: Sixty-two patients who have had a mandibulectomy performed with or without preoperative radiotherapy and chemotherapy were the study subjects.
  • This retrospective study investigated the correlation between the preoperative radiographic appearance and histopathologic findings of the excised tissue.
  • The results of the treatments were evaluated.
  • However, in 7 (36.8%) of the cases with moth-eaten type bone defects, the extent of bone involvement exceeded the bone defects detected by radiography.
  • CONCLUSIONS: Marginal resection was effective in controlling mandibular alveolus and gingival cancers when radiologically detected erosive bone defects did not extend beyond the mandibular canal.
  • [MeSH-major] Alveolectomy / methods. Carcinoma, Squamous Cell / surgery. Gingivectomy / methods. Mandibular Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alveolar Process / pathology. Chemotherapy, Adjuvant. Female. Gingiva / pathology. Humans. Male. Mandible / pathology. Mandible / radiography. Mandible / surgery. Middle Aged. Neoplasm Recurrence, Local / pathology. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15218562.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Tu HP, Fu E, Chen YT, Wu MH, Cheng LC, Yang SF: Expression of p21 and p53 in rat gingival and human oral epithelial cells after cyclosporine A treatment. J Periodontal Res; 2008 Feb;43(1):32-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p21 and p53 in rat gingival and human oral epithelial cells after cyclosporine A treatment.
  • BACKGROUND AND OBJECTIVE: Expression of p21 and p53 were examined, at gene and protein levels, in edentulous gingival epithelial cells from rats and from a human oral epidermoid carcinoma cell line, OECM1, after cyclosporine A therapy.
  • After the rats were killed, p21 and p53 in gingiva were evaluated by reverse transcription-polymerase chain reaction and immunohistochemistry.
  • In vitro: after cyclosporine A treatment, p21 and p53 of OECM1 cells were evaluated by western blot and the luciferase assay.
  • The distribution of OECM1 cells in each phase of the cell cycle was evaluated by flow cytometry.
  • A greater number of positive anti-p21-stained cells were observed in the gingival epithelium of the cyclosporine A group than in the control group.
  • Significantly higher levels of p21 protein and activity were observed in OECM1 cells after cyclosporine A treatment than in cells without treatment.
  • A relative increase of cells in G0/G1 phases, and a decrease of cells in G2/M phases, were observed in OECM1 cells after cyclosporine A treatment.
  • CONCLUSION: In the present study, higher p21 mRNA and protein expressions were observed after cyclosporine A treatment.
  • Thus, an up-regulation of p21 expression, via a p53-independent pathway, by cyclosporine A in gingival and oral epithelial cells was suggested.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p21 / analysis. Cyclosporine / therapeutic use. Genes, p53 / drug effects. Immunosuppressive Agents / therapeutic use. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell. Cell Line, Tumor. Epithelial Cells / drug effects. Gingiva / chemistry. Gingiva / cytology. Gingiva / drug effects. Humans. Jaw, Edentulous, Partially / enzymology. Jaw, Edentulous, Partially / genetics. RNA, Messenger / analysis. Rats

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18230104.001).
  • [ISSN] 1600-0765
  • [Journal-full-title] Journal of periodontal research
  • [ISO-abbreviation] J. Periodont. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Immunosuppressive Agents; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


21. Tagawa T, Tomita T, Yamaguchi H, Ozawa H, Sakamoto K, Ogawa K, Fujii M: [Clinical study of 28 cases of cervical lymph node metastasis from an unknown primary carcinoma]. Nihon Jibiinkoka Gakkai Kaiho; 2007 Jul;110(7):506-12
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of 28 cases of cervical lymph node metastasis from an unknown primary carcinoma].
  • From 1989 to 2005, 28 patients--20 men and 8 women--with cervical lymph node metastasis from an unknown primary carcinoma were treated and studied retrospectively.
  • In histological diagnosis, open biopsy was conducted in 11 patients and non-open biopsy (FNA or frozen section diagnosis during surgery) in 17.
  • Tonsillectomy for diagnosis was not done.
  • The histopathological diagnosis of cervical lymph node was as follows: squamous cell carcinoma in 21, adenocarcinoma in 3, mucoepidermoid carcinoma in 2, and others in 2.
  • Therapy was as follows: only neck dissection in 7, neck dissection with postoperative radiation therapy in 13, and irradiation and chemotherapy in 8.
  • All patients treated with irradiation and chemotherapy had been judged to be inoperable.
  • Primary tumor sites were as follows: tonsils in 3 and upper gingiva, base of tongue, lung, and nasopharynx in 1 each.
  • We should pay particular attention to the tonsils for detecting primary tumors in patients with cervical metastasis from an unknown primary carcinoma.
  • [MeSH-major] Head and Neck Neoplasms / secondary. Lymph Nodes / pathology. Lymphatic Metastasis / diagnosis. Neoplasms, Unknown Primary / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695298.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


22. Lee YJ, Liao PH, Chen WK, Yang CY: Preferential cytotoxicity of caffeic acid phenethyl ester analogues on oral cancer cells. Cancer Lett; 2000 May 29;153(1-2):51-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine chemicals were tested by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay on the growth of buccal mucosal fibroblast (BF), oral submucosus fibroblast (OSF), neck metastasis of Gingiva carcinoma (GNM), and tongue squamous cell carcinoma (TSCCa) cells.
  • The results suggest that CAPE-like compounds may be potential chemotherapy agents against oral cancer.
  • [MeSH-minor] Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Humans. Mouth Neoplasms / pathology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Oral cancer.
  • Hazardous Substances Data Bank. 2-PHENYLETHANOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10779629.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Caffeic Acids; G960R9S5SK / caffeic acid phenethyl ester; ML9LGA7468 / Phenylethyl Alcohol
  •  go-up   go-down


23. Babich H, Krupka ME, Nissim HA, Zuckerbraun HL: Differential in vitro cytotoxicity of (-)-epicatechin gallate (ECG) to cancer and normal cells from the human oral cavity. Toxicol In Vitro; 2005 Mar;19(2):231-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study evaluated the biologic activity of epicatechin gallate (ECG), a polyphenol in tea, to carcinoma HSC-2 cells and normal HGF-2 fibroblasts cells from the human oral cavity.
  • For the HSC-2 carcinoma cells, ECG, catechin gallate (CG), and epigallocatechin gallate (EGCG) grouped as highly toxic, epigallocatechin (EGC) as moderately toxic, and catechin (C) and epicatechin (EC) as least toxic.
  • The cytotoxic effects of the polyphenols were more pronounced to the carcinoma, than to the normal, cells.
  • The addition of ECG to cell culture medium led to the generation of hydrogen peroxide (H2O2).
  • DNA fragmentation, caspase-3 activity, and nuclear staining, both with acridine orange and the TUNEL procedure, were used to assess ECG-induced apoptosis.
  • ECG induced apoptosis in the carcinoma HSC-2 cells, but not in the normal HGF-2 fibroblasts.
  • This research supports those studies suggesting that tea green is an effective chemopreventive agent of oral carcinoma.
  • [MeSH-major] Antioxidants / pharmacology. Carcinoma, Squamous Cell / drug therapy. Catechin / analogs & derivatives. Catechin / pharmacology. Fibroblasts / drug effects. Gingiva / cytology. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Cell Survival / drug effects. DNA / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Humans. Structure-Activity Relationship. Tumor Cells, Cultured / drug effects

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15649637.001).
  • [ISSN] 0887-2333
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / catechin gallate; 1617-55-6 / gallocatechol; 8R1V1STN48 / Catechin; 9007-49-2 / DNA; 92587OVD8Z / epicatechin gallate; BQM438CTEL / epigallocatechin gallate
  •  go-up   go-down


24. Kawase M, Sakagami H, Furuya K, Kikuchi H, Nishikawa H, Motohashi N, Morimoto Y, Varga A, Molnár J: Cell death-inducing activity of opiates in human oral tumor cell lines. Anticancer Res; 2002 Jan-Feb;22(1A):211-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell death-inducing activity of opiates in human oral tumor cell lines.
  • Human oral gingival fibroblasts (HGF) were relatively resistant to codeinone, as judged by higher SI ratio (3.7) suggesting the tumor-selective cytotoxicity of codeinone.
  • These data suggest that codeinone induces cytotoxicity in oral tumor cell lines, possibly by a Michael-like addition of a protein SH or of an amino group to the bouble bond of codeinone.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Codeine / analogs & derivatives. Morphine Derivatives / toxicity. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Animals. Cell Death / drug effects. Child. Drug Resistance, Multiple. Female. Fibroblasts / cytology. Fibroblasts / drug effects. Fibroblasts / metabolism. Gingiva / cytology. HL-60 Cells / cytology. HL-60 Cells / drug effects. HL-60 Cells / metabolism. Humans. Leukemia L5178 / drug therapy. Leukemia L5178 / genetics. Leukemia L5178 / metabolism. Leukemia L5178 / pathology. Mice. P-Glycoprotein / biosynthesis. P-Glycoprotein / genetics. Structure-Activity Relationship. Transfection

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. CODEINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12017290.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Morphine Derivatives; 0 / P-Glycoprotein; 467-13-0 / 6-codeinone; Q830PW7520 / Codeine
  •  go-up   go-down


25. Terasawa K, Sugita Y, Yokoe I, Fujisawa S, Sakagami H: Cytotoxic activity of 2-aminomethylene-3(2H)-benzofuranones against human oral tumor cell lines. Anticancer Res; 2001 Sep-Oct;21(5):3371-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic activity of 2-aminomethylene-3(2H)-benzofuranones against human oral tumor cell lines.
  • A total of 23 newly-synthesized 2-aminomethylene-3(2H)-benzofuranone and structurally-related compounds were compared for their cytotoxic activity against both normal (human gingival fibroblast HGF) and tumor cells (human oral squamous cell lines HSC-2, HSC-3 and human salivary gland tumor cells HSG).
  • There was a significant variability of drug sensitivity among the oral tumor cell lines.
  • The most active compounds induced internucleosomal DNA fragmentation in human promyelocytic leukemia HL-60 cells, but not in HSG, further confirming that oral tumor cell lines are resistant to DNase digestion.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Benzofurans / pharmacology. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Drug Screening Assays, Antitumor. Fibroblasts / drug effects. Gingiva / cytology. Gingiva / drug effects. Humans. Piperidines / chemical synthesis. Piperidines / chemistry. Piperidines / pharmacology. Salivary Gland Neoplasms / drug therapy. Structure-Activity Relationship. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11848496.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzofurans; 0 / Piperidines
  •  go-up   go-down


26. Weisburg JH, Schuck AG, Silverman MS, Ovits-Levy CG, Solodokin LJ, Zuckerbraun HL, Babich H: Pomegranate extract, a prooxidant with antiproliferative and proapoptotic activities preferentially towards carcinoma cells. Anticancer Agents Med Chem; 2010 Oct 1;10(8):634-44
Hazardous Substances Data Bank. HYDROGEN PEROXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pomegranate extract, a prooxidant with antiproliferative and proapoptotic activities preferentially towards carcinoma cells.
  • In cell-free systems, PE generated hydrogen peroxide (H(2)O(2)) in cell culture media and in phosphate buffered saline, with prooxidant activity increasing from acidic to alkaline pH, and oxidized glutathione (GSH) in an alkaline, phosphate buffer.
  • Detection of PE-generated H(2)O(2) was greatly lessened in medium amended with N-acetyl-L-cysteine.
  • Using HSC-2 carcinoma cells as the bioindicator, the cytotoxicity of PE was potentiated towards cells pretreated with the GSH depleter, 1-chloro-2,4-dinitrobenzene, and attenuated in cells co-treated with the H(2)O(2) scavengers, catalase, pyruvate, and divalent cobalt ion.
  • Intracellular GSH was lessened in cells treated with PE; GSH depletion in PE-treated cells was confirmed visually with the fluorescent dye, Cell Tracker™ Green 5-chloromethylfluorescein diacetate.
  • The mode of cell death was by apoptosis, as shown by flow cytometry, activation of caspase-3, and cleavage of PARP.
  • [MeSH-major] Apoptosis / drug effects. Carcinoma, Squamous Cell / drug therapy. Cell Proliferation / drug effects. Neoplasms / drug therapy. Phytotherapy. Plant Extracts / pharmacology. Punicaceae. Reactive Oxygen Species / pharmacology
  • [MeSH-minor] Cell Line. Cell Line, Tumor. Fibroblasts / metabolism. Flow Cytometry. Fruit. Gingiva / metabolism. Glutathione / metabolism. Humans. Hydrogen Peroxide / metabolism. Oxidative Stress / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21184666.001).
  • [ISSN] 1875-5992
  • [Journal-full-title] Anti-cancer agents in medicinal chemistry
  • [ISO-abbreviation] Anticancer Agents Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Reactive Oxygen Species; BBX060AN9V / Hydrogen Peroxide; GAN16C9B8O / Glutathione
  •  go-up   go-down


27. Nakashiro K, Shintani S, Yano J, Shinohara Y, Terakado N, Hamakawa H: [A case of mandibular gingival cancer (T4) responding to concurrent chemoradiotherapy with TS-1]. Gan To Kagaku Ryoho; 2003 Sep;30(9):1309-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of mandibular gingival cancer (T4) responding to concurrent chemoradiotherapy with TS-1].
  • The patient was an 82-year-old male who had a 41 x 22 mm tumor mass around the left lower gingiva, whose X-ray showed a bone resorption image reaching the mandibular canal.
  • After 4 weeks, severe side effects, i.e., stomatitis and diarrhea, force us to discontinue the treatment.
  • However, the tumor had begun to shrink from the 2nd week of treatment, and had clinically disappeared by the 8th week.
  • Thus, this treatment was very effective and may be useful for advanced cases.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Gingival Neoplasms / drug therapy. Gingival Neoplasms / radiotherapy. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Administration Schedule. Drug Combinations. Humans. Male. Mandible. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14518411.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


28. Sugita Y, Hosoya H, Terasawa K, Yokoe I, Fujisawa S, Sakagami H: Cytotoxic activity of benzothiepins against human oral tumor cell lines. Anticancer Res; 2001 Jul-Aug;21(4A):2629-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic activity of benzothiepins against human oral tumor cell lines.
  • All these compounds showed higher cytotoxic activity against three human oral tumor cell lines (HSC-2, HSC-3, HSG) than against normal human gingival fibroblast (HGF), suggesting tumor-specific cytotoxic action.
  • [MeSH-major] Antineoplastic Agents / toxicity. Benzothiepins / toxicity. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. Drug Screening Assays, Antitumor. Fibroblasts / cytology. Fibroblasts / drug effects. Gingiva / cytology. Gingiva / drug effects. HL-60 Cells / drug effects. Humans. Salivary Gland Neoplasms / drug therapy. Structure-Activity Relationship. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11724331.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzothiepins
  •  go-up   go-down


29. Jiang Y, Satoh K, Aratsu C, Komatsu N, Fujimaki M, Nakashima H, Kanamoto T, Sakagami H: Diverse biological activity of polycaphenol. In Vivo; 2001 Mar-Apr;15(2):145-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Millimolar concentrations of alkaline extract of Cacao husk (polycaphenol) were more cytotoxic to human oral tumor cells (human oral squamous cell carcinoma HSC-2, human salivary gland tumor HSG), than to human gingival fibroblast (HGF), suggesting its tumor-specific action.
  • [MeSH-major] Escherichia coli Infections / drug therapy. Free Radical Scavengers / pharmacology. Gingiva / cytology. Lignin / pharmacology
  • [MeSH-minor] Animals. Antineoplastic Agents, Phytogenic / pharmacology. Cacao / chemistry. Carcinoma, Squamous Cell. Cytotoxins / pharmacology. Fibroblasts / cytology. Fibroblasts / drug effects. HIV Infections / drug therapy. Humans. Male. Mice. Mouth Neoplasms. Salivary Gland Neoplasms. Tumor Cells, Cultured. Vitamins / pharmacology

  • MedlinePlus Health Information. consumer health - E. Coli Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11317519.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Cytotoxins; 0 / Free Radical Scavengers; 0 / Vitamins; 0 / polycaphenol; 9005-53-2 / Lignin
  •  go-up   go-down


30. Gomez DR, Zhung JE, Gomez J, Chan K, Wu AJ, Wolden SL, Pfister DG, Shaha A, Shah JP, Kraus DH, Wong RJ, Lee NY: Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers. Int J Radiat Oncol Biol Phys; 2009 Mar 15;73(4):1096-103
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers.
  • METHODS AND MATERIALS: Between September 2000 and December 2006, 35 patients with histologically confirmed squamous cell carcinoma of the oral cavity underwent surgery followed by postoperative IMRT.
  • The sites included were buccal mucosa in 8, oral tongue in 11, floor of the mouth in 9, gingiva in 4, hard palate in 2, and retromolar trigone in 1.
  • Ten patients (29%) also received concurrent postoperative chemotherapy with IMRT.
  • The median prescribed radiation dose was 60 Gy.
  • Treatment failure occurred in 11 cases as follows: local in 4, regional in 2, and distant metastases in 5.
  • CONCLUSION: IMRT as an adjuvant treatment after surgical resection for oral cavity tumors is feasible and effective, with promising results and acceptable toxicity.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Male. Middle Aged. Radiation Injuries / etiology. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707827.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


31. Okayasu H, Ishihara M, Satoh K, Sakagami H: Cytotoxic activity of vitamins K1, K2 and K3 against human oral tumor cell lines. Anticancer Res; 2001 Jul-Aug;21(4A):2387-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic activity of vitamins K1, K2 and K3 against human oral tumor cell lines.
  • Among these compounds, vitamin K3 showed the highest cytotoxic activity against human oral tumor cell lines (HSC-2, HSG), human promyelocytic leukemic cell line (HL-60) and human gingival fibroblast (HGF).
  • [MeSH-major] Mouth Neoplasms / drug therapy. Vitamin K / toxicity
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. DNA Fragmentation / drug effects. Electron Spin Resonance Spectroscopy. Fibroblasts / cytology. Fibroblasts / drug effects. Free Radical Scavengers / toxicity. Gingiva / cytology. Gingiva / drug effects. HL-60 Cells / drug effects. Humans. Models, Molecular. Salivary Gland Neoplasms / drug therapy. Structure-Activity Relationship. Superoxides / metabolism. Tumor Cells, Cultured. Vitamin K 1 / toxicity. Vitamin K 2 / toxicity. Vitamin K 3 / toxicity

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin K.
  • Hazardous Substances Data Bank. MENADIONE .
  • Hazardous Substances Data Bank. PHYTONADIONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11724297.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Free Radical Scavengers; 11032-49-8 / Vitamin K 2; 11062-77-4 / Superoxides; 12001-79-5 / Vitamin K; 723JX6CXY5 / Vitamin K 3; 84-80-0 / Vitamin K 1
  •  go-up   go-down


32. Shirataki Y, Tani S, Sakagami H, Satoh K, Nakashima H, Gotoh K, Motohashi N: Relationship between cytotoxic activity and radical intensity of isoflavones from Sophora species. Anticancer Res; 2001 Jul-Aug;21(4A):2643-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among 11 isoflavones tested, genistein [YS13] produced higher cytotoxic activity against human oral tumor cell lines (HSC-2, HSG) than against normal cells (human gingival fibroblast, HGF), suggesting its tumor-specific action.
  • [MeSH-minor] Animals. Anti-Bacterial Agents. Carcinoma, Squamous Cell / drug therapy. Cattle. Drug Screening Assays, Antitumor. Fibroblasts / cytology. Fibroblasts / drug effects. Free Radical Scavengers / chemistry. Free Radical Scavengers / pharmacology. Gingiva / cytology. Gingiva / drug effects. HIV / drug effects. Helicobacter pylori / drug effects. Humans. Mouth Neoplasms / drug therapy. Salivary Gland Neoplasms / drug therapy. Structure-Activity Relationship. Superoxides / metabolism

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11724333.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-HIV Agents; 0 / Anti-Infective Agents; 0 / Antineoplastic Agents; 0 / Free Radical Scavengers; 0 / Isoflavones; 11062-77-4 / Superoxides
  •  go-up   go-down


33. Motohashi N, Wakabayashi H, Kurihara T, Takada Y, Maruyama S, Sakagami H, Nakashima H, Tani S, Shirataki Y, Kawase M, Wolfard K, Molnár J: Cytotoxic and multidrug resistance reversal activity of a vegetable, 'Anastasia Red', a variety of sweet pepper. Phytother Res; 2003 Apr;17(4):348-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These extracts showed relatively higher cytotoxic activity against two human oral tumor cell lines (HSC-2, HSG) than against normal human gingival fibroblasts (HGF), suggesting a tumor-specific cytotoxic activity.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Capsicum. Fibroblasts / drug effects. Gingiva / drug effects. Phytotherapy. Plant Extracts / pharmacology
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / drug therapy. Drug Resistance, Multiple. Drug Resistance, Neoplasm. HIV / drug effects. Helicobacter pylori / drug effects. Humans. Lymphoma, T-Cell / drug therapy. Mice. Microbial Sensitivity Tests. Mouth Neoplasms / drug therapy. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 John Wiley & Sons, Ltd.
  • (PMID = 12722138.001).
  • [ISSN] 0951-418X
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts
  •  go-up   go-down


34. Kinoshita N, Yamamura T, Teranuma H, Katayama T, Tamanyu M, Negoro T, Satoh K, Sakagami H: Interaction between dental metals and antioxidants, assessed by cytotoxicity assay and ESR spectroscopy. Anticancer Res; 2002 Nov-Dec;22(6C):4017-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among dental metals, copper showed the highest cytotoxicity against human oral squamous cell carcinoma and human submandibular gland carcinoma cells, followed by palladium-alloy, gold and silver.
  • Normal human cells (gingival fibroblast, pulp cells, periodontal ligament fibroblast) were relatively resistant to these metals.
  • These data demonstrate for the first time that antioxidants modify the biological activity of dental metals.
  • [MeSH-minor] Ascorbic Acid / pharmacology. Carcinoma, Squamous Cell / drug therapy. Copper / chemistry. Copper / metabolism. Copper / pharmacology. Drug Interactions. Electron Spin Resonance Spectroscopy. Fibroblasts / drug effects. Free Radicals / chemistry. Free Radicals / metabolism. Gingiva / cytology. Gingiva / drug effects. Gold / chemistry. Gold / metabolism. Gold / pharmacology. HL-60 Cells / drug effects. Humans. Hypoxanthine / chemistry. Hypoxanthine / metabolism. Mouth Neoplasms / drug therapy. Palladium / chemistry. Palladium / metabolism. Palladium / pharmacology. Periodontal Ligament / cytology. Periodontal Ligament / drug effects. Reactive Oxygen Species / chemistry. Reactive Oxygen Species / metabolism. Silver / chemistry. Silver / metabolism. Silver / pharmacology. Submandibular Gland Neoplasms / drug therapy. Tumor Cells, Cultured. Xanthine Oxidase / chemistry. Xanthine Oxidase / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • Hazardous Substances Data Bank. PALLADIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. SILVER, ELEMENTAL .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12553026.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Dental Materials; 0 / Free Radicals; 0 / Metals; 0 / Reactive Oxygen Species; 2TN51YD919 / Hypoxanthine; 3M4G523W1G / Silver; 5TWQ1V240M / Palladium; 7440-57-5 / Gold; 789U1901C5 / Copper; EC 1.17.3.2 / Xanthine Oxidase; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


35. Yanamoto S, Kawasaki G, Yoshida H, Yoshitomi I, Iwamoto T, Mizuno A, Fujita S: Rapidly growing mass of the anterior maxillary gingiva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Aug;104(2):153-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly growing mass of the anterior maxillary gingiva.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Gingival Neoplasms / pathology. Maxilla / surgery
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Diagnosis, Differential. Granulomatosis with Polyangiitis / diagnosis. Humans. Male. Maxillary Sinus Neoplasms / drug therapy. Maxillary Sinus Neoplasms / pathology. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / surgery. Mycoses / diagnosis. Nose Neoplasms / drug therapy. Nose Neoplasms / pathology. Nose Neoplasms / radiotherapy. Nose Neoplasms / surgery. Palatal Neoplasms / drug therapy. Palatal Neoplasms / pathology. Palatal Neoplasms / radiotherapy. Palatal Neoplasms / surgery. Radiotherapy, Adjuvant. Tuberculosis, Oral / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449292.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement